Highest-materiality recent filing
Arcturus Q2 net loss $23.8M; regains KOSTAIVE rights; ARCT-032 Phase 3 decision Q4 2026
Net loss of $23.8M ($0.84/share) vs $9.2M ($0.34/share) in Q2 2025; revenue fell to $3.0M from $28.3M due to CSL Seqirus termination.
Arcturus signs $80M collaboration with Thermo Fisher for ARCT-032 CF program
Thermo Fisher to provide up to $40M in clinical manufacturing services; Arcturus to spend up to $40M on CRO services via PPD.
Arcturus Q1 net loss widens to $27M; appoints Dennis Mulroy as CFO
Net loss of $27.0M ($0.95/diluted share), compared to $14.1M loss ($0.52/share) in Q1 2025.
Arcturus FY2025 net loss narrows to $65.8M; revenue falls 46% to $82M; CF program advances
Q4 net loss $29.1M ($1.03/shr) vs $30.0M loss prior year; FY net loss $65.8M ($2.40/shr) vs $80.9M.
CFO Andy Sassine to depart Dec 31, 2025; Controller Joe Roberts named interim CFO
CFO Andy Sassine and Arcturus mutually agreed to end employment effective Dec 31, 2025; he also resigned from the Board.
Arcturus Therapeutics Reports Q3 2025 Net Loss of $13.5M, Progresses ARCT-032 and ARCT-810 Programs
Q3 2025 revenue was $17.2M, down $24.5M from prior year; net loss $13.5M ($0.49 per share) vs $6.9M loss in Q3 2024.
ARCT-032 Phase 2 interim: generally safe/tolerated; 4 of 6 Class I CF patients showed mucus plug/volume reduction after 28 days (10 mg).
Meiji Seika Pharma receives Japan approval for two-dose vial of KOSTAIVE® COVID-19 vaccine
Approval granted August 28, 2025 for new two-dose vial presentation of KOSTAIVE® (ARCT-2301) in Japan.
Arcturus ARCT-810 Phase 2 interim: glutamine normalized, ureagenesis improved (p=0.026)
Combined Phase 2 data show glutamine significantly reduced (p=0.0055); levels normalized after 3 doses in US study.
Arcturus Q1 net loss narrows to $14.1M; cash runway extends into 2028
Net loss $14.1M ($0.52/diluted share) vs $26.8M ($1.00) a year ago; revenue $29.4M down 23% YoY.
Arcturus Q4 net loss widens to $30M; KOSTAIVE EC approved, Phase 2 data due Q2 2025
Q4 2024 net loss $30.0M ($1.11/share) vs $11.7M ($0.44) in Q4 2023; revenue down $8.1M to $22.8M.
Arcturus Q3 net loss narrows to $6.9M; $25M milestone from KOSTAIVE first sale in Japan
Q3 revenue $41.7M vs $45.2M YoY, down on lower CSL milestones; net loss $6.9M ($0.26/sh) vs $16.2M ($0.61/sh).
Arcturus Q2 revenue $49.9M, net loss $17.2M; pipeline advances, Kostaive launch on track
Revenue $49.9M, up $39.4M YoY from $10.5M, driven by CSL collaboration revenue.
Q1 2024 revenue $38.0M (down 53% YoY); net loss $26.8M ($1.00/share) vs net income $50.8M ($1.87) in Q1 2023.
Arcturus partner Meiji reports Phase III success for bivalent COVID-19 booster in Japan
Bivalent ARCT-2301 (Kostaive) met primary endpoint of non-inferiority vs COMIRNATY bivalent in GMT ratio and SRR difference.
Arcturus Therapeutics amends FY2023 results: revenue down $3.2M, net loss wider
Collaboration revenue for FY2023 decreased from $160.9M to $157.7M; Q4 2023 from $28.2M to $25.0M.
Arcturus FY2023 revenue $169.9M, net loss $26.6M; cash runway extended to Q1 2027
FY2023 revenue $169.9M (down from $206.0M); net loss $26.6M ($1.00 diluted EPS) vs prior year net income $9.3M ($0.35 EPS).
Revenue of $45.1M for Q3 2023 ($13.4M in Q3 2022); net loss $16.2M ($0.61/share) improved from $35.3M loss.
Arcturus' JV ARCALIS awarded $115M in Japanese government grants; achieves $17.5M CSL flu milestone
ARCALIS, Arcturus' 49%-owned joint venture, receives $115M in two grants to build a cGMP mRNA factory in Minamisoma, Japan.
Arcturus Q2 net loss widens to $52.6M; ARCT-154 NDA submitted in Japan
Q2 2023 revenue $10.5M vs $27.1M in Q2 2022; net loss $52.6M ($1.98 EPS) vs $21.6M loss ($0.82 EPS).
Arcturus announces medRxiv preprint of Phase 3 data for ARCT-154 booster vs. Comirnaty
Preprint on medRxiv reports interim Phase 3 results from Japan comparing ARCT-154 booster to Comirnaty.
Meiji Seika Pharma submitted a booster dose application for ARCT-154 in Japan based on Phase III data meeting primary endpoint.
Revenue $80.3M (up from $5.2M YoY) driven by CSL Seqirus milestones; net income $50.8M vs loss of $51.2M.
Meiji submits NDA in Japan for ARCT-154, Arcturus' self-amplifying mRNA COVID-19 vaccine
Meiji Seika Pharma filed NDA for primary immunization (two doses) of ARCT-154 in Japan.
Meiji and CSL Seqirus to distribute Arcturus' COVID-19 vaccine ARCT-154 in Japan
Meiji Seika Pharma entered a distribution agreement with CSL Seqirus for Arcturus' COVID-19 vaccine candidate ARCT-154 in Japan.
Arcturus Q4 2022 net income $117.3M ($4.33/diluted share), revenue surge to $160.3M on CSL deal
Q4 2022 revenue $160.3M vs $5.8M same quarter 2021; full-year revenue $206.0M vs $12.4M.
Arcturus' COVID-19 vaccine ARCT-154 enters Phase III trial in Japan; CSL collaboration effective
Meiji Seika Pharma initiated a Phase III trial of ARCT-154 (self-amplifying mRNA COVID-19 vaccine) in Japan with 780 participants; half receive ARCT-154 as a booster.
Arcturus Q3 net loss $35.3M; CSL partnership $200M upfront, up to $4.3B milestones
Revenue $13.4M (Q3 2022) vs $2.4M YoY; net loss $35.3M ($1.33 per share).
Arcturus: Janssen ends Hep B pact, Vietnam mfg deal terminated; ARCT-154 study extended
Janssen terminated Hep B collaboration; effective in 60 days; no penalties.
Arcturus signs $200M upfront collaboration with CSL Seqirus for self-amplifying mRNA vaccines
Arcturus receives $200M upfront; eligible for >$1.3B development and >$3B commercial milestones.
Arcturus receives $63.2M BARDA award to develop self-amplifying mRNA pandemic flu vaccine
BARDA provides up to $63.2 million over three years for pandemic influenza vaccine development using STARR self-amplifying mRNA platform.
Arcturus Q2 revenue $27.1M, net loss $0.82/share; ARCT-154 booster shows durable Omicron response
Revenue $27.1M (vs $2.0M Q2 2021); net loss $21.6M ($0.82/sh) improved from $54.6M ($2.07/sh) year ago.
Arcturus Q1 net loss $51.2M ($1.94/share); ARCT-154 booster shows 54-fold Omicron BA.1 response
Q1 2022 revenue $5.2M (up from $2.1M YoY); operating expenses $55.6M; net loss $51.2M.
Arcturus ARCT-154 Phase 3 shows 55% efficacy vs COVID-19, 95% vs severe disease
Two 5-mcg doses of ARCT-154 provided 55% efficacy (95% CI 46.9-61.9) against symptomatic COVID-19.
Effective May 1, 2026, Dennis Mulroy, 71, was appointed Chief Financial Officer of the Company.
On June 19, 2024, Dr. Moncef Slaoui, Ph.D., agreed to serve as a member of the Board of Directors
Joseph Roberts, formerly the Company’s Assistant Controller, has been promoted to Controller of the Company.
Keith C. Kummerfeld, Senior Vice President of Finance and Corporate Controller of Arcturus Therapeutics Holdings Inc. (the “Company” or “Arcturus”), informed the Company that he will resign from his position with the Company, effective March 15, 2024, to pursue another opportunity.
On December 8, 2022, Dr. John Markels agreed to serve as a member of the Board of Directors of Arcturus Therapeutics Holdings Inc.
Effective February 14, 2022, Dr. Steve Hughes will step down from his position as Chief Medical Officer of Arcturus Therapeutics Holdings Inc.
Dr. Kelly Lindert, the Company’s Senior Vice President and Head of Vaccines, will take on the role of Chief Development Officer, Vaccines, for the Company.
the Board subsequently appointed Dr. Jing Marantz to serve as a director of the Company, effective as of December 7, 2021
On August 25, 2021, Karah Parschauer notified the board of directors (the “Board”) of Arcturus Therapeutics Holdings Inc. (the “Company”) of her resignation from the Board and any associated committees of the Board, effective August 25, 2021.
Max materiality 0.90 · Median 0.65 · Most common event other_material